The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Novel ways of regulating epithelial transport. This project is intended to discover novel intracellular mechanisms that regulate the rate of ion transport by the lung, the gut and the kidney. It will not only provide new insights into how the body controls a process that is critical to animal life, but also provide new targets for the development of pharmaceuticals.
Of pets, vets and antimicrobials: fluoroquinolone use in dogs and resistance biology. Antimicrobial resistance is a current and growing threat relevant to human health, animal welfare, food production, and environmental preservation. This project will provide new insights into the basic science of antimicrobial resistance, through the generation of accurate data on the role of companion animal use of antibiotics on the development and control of resistance. Ultimate project goals are to produce ....Of pets, vets and antimicrobials: fluoroquinolone use in dogs and resistance biology. Antimicrobial resistance is a current and growing threat relevant to human health, animal welfare, food production, and environmental preservation. This project will provide new insights into the basic science of antimicrobial resistance, through the generation of accurate data on the role of companion animal use of antibiotics on the development and control of resistance. Ultimate project goals are to produce recommendations that limit the generation of further resistance. Project outcomes have demonstrable relevance to human preventative health, which is recognised as a national research priority. The health and welfare of pets will also be improved, which has associated community benefits.Read moreRead less
Neurotrophic Active Natural Products: Total Synthesis and Biological Evaluation of Neovibsanins A and B, and Analogues. New chemical entities (drug candidates) that promote neurite outgrowth have significant ramifications to mankind as they have real potential to repair damaged, or grow replacement, nerve cells affected by neuro and central nervous system (CNS) degenerative disease (e.g. Alzhiemer's, Parkinson's, Huntington's etc). This scientific endeavour will reveal new drug like molecules fo ....Neurotrophic Active Natural Products: Total Synthesis and Biological Evaluation of Neovibsanins A and B, and Analogues. New chemical entities (drug candidates) that promote neurite outgrowth have significant ramifications to mankind as they have real potential to repair damaged, or grow replacement, nerve cells affected by neuro and central nervous system (CNS) degenerative disease (e.g. Alzhiemer's, Parkinson's, Huntington's etc). This scientific endeavour will reveal new drug like molecules for potential biological and clinical application, thereby assisting a substantial proportion of Australians suffering from these debilitating diseases. Read moreRead less
NMR Studies of Second Generation Polynuclear Platinum Compounds. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these ne ....NMR Studies of Second Generation Polynuclear Platinum Compounds. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students.Read moreRead less
DNA interactions of polynuclear platinum. Mechanistic NMR studies probing the origin of the unique antitumour activity of BBR3464. BBR3464 is one of a class of structurally unique platinum anticancer drugs that is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is quite different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow the processes involved in the initial binding of the dr ....DNA interactions of polynuclear platinum. Mechanistic NMR studies probing the origin of the unique antitumour activity of BBR3464. BBR3464 is one of a class of structurally unique platinum anticancer drugs that is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is quite different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow the processes involved in the initial binding of the drug to DNA and the subsequent reactions of the adducts formed. The results of this work will aid in the selection of back-up clinical candidates and in the design of drugs that target specific sequences of DNA for use in novel gene-based therapies.Read moreRead less
Emulsion Stability and Solvent Extraction Equipment Design in the Pharmaceutical Industry. The project aims at developing reliable prediction of large scale performance of liquid extraction columns. This will be done through a study of the columns in operation at GlaxoSmithKline's operation at Port Fairy alkaloids plant. In addition a detailed study of the influence of impurities on the coalescence rate of liquid dispersions will be undertaken as this is an important rate limiting step in colu ....Emulsion Stability and Solvent Extraction Equipment Design in the Pharmaceutical Industry. The project aims at developing reliable prediction of large scale performance of liquid extraction columns. This will be done through a study of the columns in operation at GlaxoSmithKline's operation at Port Fairy alkaloids plant. In addition a detailed study of the influence of impurities on the coalescence rate of liquid dispersions will be undertaken as this is an important rate limiting step in column performance. The benefit to GlaxoSmithKline will be a more efficient and optimised plant. The benefit to Australian processing industries is a reliable method of relating small scale trials to full size column performance which is a significent problem in the minerals industry at present.Read moreRead less
Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at t ....Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students. Read moreRead less
Next Generation of Separation Equipment for Natural Product Extraction. The benefit to GlaxoSmithKline will be the potential to upgrade to a more efficient plant which is important for maintaining their competitive position in this global business. The benefit to other Australian processing industries will be an improved understanding of the performance of membrane contactors when used for natural product separation and more specifically a reliable method for controlling fouling in this type of ....Next Generation of Separation Equipment for Natural Product Extraction. The benefit to GlaxoSmithKline will be the potential to upgrade to a more efficient plant which is important for maintaining their competitive position in this global business. The benefit to other Australian processing industries will be an improved understanding of the performance of membrane contactors when used for natural product separation and more specifically a reliable method for controlling fouling in this type of equipment which is a currently a significant industry problem.Read moreRead less
Design, Evaluation, and Selection of Novel Pt(IV) Complexes as Anticancer Agents. Platinum anticancer drugs are arguably the most widely used anticancer agents in the world but serious problems remain with toxicity and resistance. Platinum(IV) compounds have numerous advantages in terms of stability and thereby, lower toxicity. In this project we will exploit these advantages along with others that we have discovered recently and our understanding of the chemistry and biology of platinum(IV) to ....Design, Evaluation, and Selection of Novel Pt(IV) Complexes as Anticancer Agents. Platinum anticancer drugs are arguably the most widely used anticancer agents in the world but serious problems remain with toxicity and resistance. Platinum(IV) compounds have numerous advantages in terms of stability and thereby, lower toxicity. In this project we will exploit these advantages along with others that we have discovered recently and our understanding of the chemistry and biology of platinum(IV) to develop novel platinum(IV) compounds to the point where the industry partner can commercialise them.Read moreRead less
Characterisation of insulin-independent glucose uptake mediated by guanine nucleotide-binding proteins (G-proteins) coupled receptors. This project will provide first class postdoctoral training for Dr Sato in the laboratory of A/Prof Bengtsson one of the pioneers in the field of cell metabolism. He will learn new approaches to the study of cell signalling including the use of ribonucleic acid interference (RNAi) technologies and of a series of functionally altered mutants of phosphatidylinosito ....Characterisation of insulin-independent glucose uptake mediated by guanine nucleotide-binding proteins (G-proteins) coupled receptors. This project will provide first class postdoctoral training for Dr Sato in the laboratory of A/Prof Bengtsson one of the pioneers in the field of cell metabolism. He will learn new approaches to the study of cell signalling including the use of ribonucleic acid interference (RNAi) technologies and of a series of functionally altered mutants of phosphatidylinositol (PI) 3-kinase that he will bring back to Monash University. A better understanding of the cell signalling mechanisms involved in glucose transport will be of enormous benefit in developing new approaches to the treatment of diseases such as type II diabetes.Read moreRead less